Passage Bio, INC. (PASG) — 10-Q Filings

10-Q Filings (6)

• Passage Bio Narrows Q3 Loss Amid R&D Cuts, Cash Position Improves — Nov 10, 2025 Risk: high
  Passage Bio, Inc. reported a net loss of $7.7 million for the three months ended September 30, 2025, a significant improvement from the $19.3 million net loss i
• Passage Bio Narrows Losses, Boosts Cash Amid R&D Cuts — Aug 12, 2025 Risk: high
  Passage BIO, Inc. reported a net loss of $9.385 million for the three months ended June 30, 2025, a significant improvement from the $15.991 million net loss in
• Passage BIO, Inc. Files Q1 2025 10-Q — May 13, 2025 Risk: medium
  Passage BIO, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the biological products sector. Its pr
• Passage BIO, Inc. Files Q3 2024 10-Q — Nov 13, 2024 Risk: low
  Passage BIO, Inc. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in the biological products sector. Ke
• Passage BIO Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Passage BIO, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and operational updates. Key financial figures and
• Passage BIO, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  Passage BIO, Inc. (PASG) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Passage BIO, Inc. filed a 10-Q report for the period ending March 31, 202

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX